Ms. Helfrich’s focus is lung cancer research. She investigates the efficacy of novel molecularly targeted agents in both non-small cell (NSCLC) and small cell lung cancer (SCLC). Following the determination of drug efficacy in a large panel of lung cancer cell lines she attempts to determine biomarkers that can then be used in clinical trials to select patients that are most likely to respond to the novel agent.
Casas-Selves M, Kim J, Zhang S, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Tan AC, Degregorie J. Genome wide shRNA screens reveal that tankyrase and the canonical WNT pathway protect lung cancer cells from EGFR inhibition. Cancer Research 2012 June 27th Eupub.
Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasle LE. (2010). Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines thorough de-repression of FGFR2 and FGFR3. PlosOne 5(11):e14117.
Collaborator: Targeting pathways that relieve proteotoxic stress to inhibit ALK+ NSCLC cell growth: Funding Source: Spore in Lung Cancer Pilot Project 7/1/2012-6/30/2012.
Collaborator: Rationally designed targeted therapeutic approaches for NSCLC: Funding Source: National Institute of Health 4/01/2012 to 3/31/2016.
Co-Inv: Development and Testing of Neuropeptide Signal Pathways for the Treatment and Chemoprevention of Lung Cancer: Funding Source: National Cancer Institute 9/30/92-5/30/13